Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALLK Stock Forecast 2026-2027
$0.33
Current Price
$29.74M
Market Cap
Buy 0
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to ALLK Price Targets
-8.8%
To High Target of $0.30
-8.8%
To Median Target of $0.30
-8.8%
To Low Target of $0.30
ALLK Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
0.0%
1 Year Change
0.0%
Year-to-Date Change
-78.9%
From 52W High of $1.56
+49.6%
From 52W Low of $0.22
📊 TOP ANALYST CALLS
Did ALLK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Allakos is one of their latest high-conviction picks.
Latest ALLK Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, ALLK has a neutral consensus with a median price target of $0.30 (ranging from $0.30 to $0.30). The overall analyst rating is Buy (6.0/10). Currently trading at $0.33, the median forecast implies a -8.8% downside. This outlook is supported by 0 Buy, 3 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALLK Analyst Ratings
0
Buy
3
Hold
0
Sell
ALLK Price Target Range
Low
$0.30
Average
$0.30
High
$0.30
Current: $0.33
Latest ALLK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALLK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 26, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $3.00 |
| Jul 18, 2024 | Jefferies | Kevin Strang | Hold | Maintains | $1.00 |
| Jun 26, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $3.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Jennifer Kim | Neutral | Reiterates | $N/A |
| Jan 17, 2024 | Barclays | Carter Gould | Underweight | Maintains | $1.00 |
| Jan 17, 2024 | Jefferies | Kevin Strang | Hold | Downgrade | $1.50 |
| Jan 17, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $3.00 |
| Dec 18, 2023 | William Blair | Tim Lugo | Outperform | Upgrade | $N/A |
| Dec 8, 2023 | Jefferies | Kevin Strang | Buy | Assumes | $6.00 |
| Nov 28, 2023 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $10.00 |
| Nov 14, 2023 | Barclays | Carter Gould | Underweight | Maintains | $1.50 |
| Nov 14, 2023 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $10.00 |
| Sep 27, 2023 | JMP Securities | Jonathan Wolleben | Market Outperform | Initiates | $11.00 |
| May 12, 2023 | Jefferies | Maury Raycroft | Buy | Upgrade | $9.00 |
| Mar 7, 2023 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $7.00 |
| Mar 7, 2023 | Piper Sandler | Yasmeen Rahimi | Overweight | Initiates | $22.00 |
| Feb 27, 2023 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $7.00 |
| Jan 27, 2023 | Morgan Stanley | Michael Ulz | Equal-Weight | Maintains | $8.00 |
| Sep 12, 2022 | Cantor Fitzgerald | Jennifer Kim | Overweight | Maintains | $7.00 |
| May 24, 2022 | Goldman Sachs | Paul Choi | Neutral | Maintains | $4.00 |
Allakos Inc. (ALLK) Competitors
The following stocks are similar to Allakos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Allakos Inc. (ALLK) Financial Data
Allakos Inc. has a market capitalization of $29.74M with a P/E ratio of -0.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -88.9%.
Valuation Metrics
Market Cap
$29.74M
Enterprise Value
$-25,493,938
P/E Ratio
-0.3x
PEG Ratio
-0.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+185.7%
Current Ratio
14.2x
Debt/Equity
0.0x
ROE
-88.9%
ROA
-52.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Allakos Inc. (ALLK) Business Model
About Allakos Inc.
What They Do
Develops antibody-based treatments for immune diseases.
Business Model
Allakos Inc. generates revenue through the development and commercialization of innovative biopharmaceutical products that target allergic, inflammatory, and proliferative diseases. The company focuses on advanced immunological research to create therapies that modulate immune responses, potentially leading to significant medical advancements in areas with high unmet needs.
Additional Information
Allakos is dedicated to pioneering solutions for conditions such as eosinophilic gastritis and eosinophilic esophagitis. By addressing niche medical issues, the company enhances the treatment landscape and contributes to the broader health science narrative, emphasizing the importance of specialized medical research for improving patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
131
CEO
Dr. Robert Alexander Ph.D.
Country
United States
IPO Year
2018
Website
www.allakos.comAllakos Inc. (ALLK) Latest News & Analysis
Latest News
Quick Summary
Allakos Inc. has announced a definitive merger agreement with Concentra Biosciences, which will acquire Allakos for $0.33 per share in cash.
Why It Matters
The merger announcement indicates a significant corporate event, potentially impacting Allakos's stock value and investor sentiment regarding the biotechnology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc. - ALLK
1 year ago
Quick Summary
Monteverde & Associates PC is investigating Allakos Inc. (NASDAQ: ALLK) regarding its proposed merger with Concentra Biosciences, LLC. The firm is noted for significant shareholder recoveries.
Why It Matters
The investigation into Allakos Inc.'s merger may indicate potential legal risks, impacting stock performance and investor confidence in the company.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating the fairness of Allakos Inc.'s sale to Concentra Biosciences for $0.33 per share, urging shareholders to explore their legal rights.
Why It Matters
The investigation into Allakos' sale price may indicate potential undervaluation, affecting shareholder sentiment and stock performance, which could influence broader market perceptions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for potential fiduciary duty breaches in its transaction with Concentra. Shareholders will receive $0.33 per share in cash.
Why It Matters
Legal investigations can signal potential risks for Allakos, affecting its stock price and investor confidence. Shareholders may face losses if fiduciary duties were indeed breached.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Allakos Inc. (Nasdaq: ALLK) reported its fourth-quarter financial results for 2024 and provided a business update on its antibody development for various diseases.
Why It Matters
Allakos Inc.'s business update and financial results could signal shifts in its growth potential and market performance, affecting investor sentiment and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kuehn Law is investigating potential fiduciary duty breaches by Allakos Inc. officers regarding self-dealing, which may lead to shareholder damages and governance reforms.
Why It Matters
The investigation into Allakos Inc. could signal potential legal issues and governance changes, affecting shareholder value and the company's stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ALLK Stock
What is Allakos Inc.'s (ALLK) stock forecast for 2027?
Based on our analysis of 13 Wall Street analysts, Allakos Inc. (ALLK) has a median price target of $0.30. The highest price target is $0.30 and the lowest is $0.30.
Is ALLK stock a good investment in 2027?
According to current analyst ratings, ALLK has 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALLK stock?
Wall Street analysts predict ALLK stock could reach $0.30 in the next 12 months. This represents a -8.8% decrease from the current price of $0.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Allakos Inc.'s business model?
Allakos Inc. generates revenue through the development and commercialization of innovative biopharmaceutical products that target allergic, inflammatory, and proliferative diseases. The company focuses on advanced immunological research to create therapies that modulate immune responses, potentially leading to significant medical advancements in areas with high unmet needs.
What is the highest forecasted price for ALLK Allakos Inc.?
The highest price target for ALLK is $0.30 from at , which represents a -8.8% decrease from the current price of $0.33.
What is the lowest forecasted price for ALLK Allakos Inc.?
The lowest price target for ALLK is $0.30 from at , which represents a -8.8% decrease from the current price of $0.33.
What is the overall ALLK consensus from analysts for Allakos Inc.?
The overall analyst consensus for ALLK is neutral. Out of 13 Wall Street analysts, 0 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $0.30.
How accurate are ALLK stock price projections?
Stock price projections, including those for Allakos Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 12:44 AM UTC